JAMA Oncology’s Post

Pancreatic cancer screening is not recommended for the general population due to the low prevalence of the disease, the inaccuracy of tests (including occasional false positives and negatives), and the high cost of the tests. However, in line with precision medicine principles, individuals at high risk for pancreatic cancer, such as those with a family history or genetic predisposition, should undergo regular screenings. Selective surveillance of high-risk individuals (with a genetic or familial predisposition) for pancreatic cancer can lead to:  • The detection of smaller, lower-stage cancers  • Improved long-term survival rates and reduced PDAC-specific mortality These findings support the potential benefit of targeted surveillance programs in improving clinical outcomes for individuals at high risk for pancreatic cancer, highlighting the importance of early detection and appropriate management. Key Findings: 1. Early Detection and Stage at Diagnosis  • Surveillance led to a higher proportion of stage I pancreatic cancers (31% in high-risk individuals vs. 10% in controls).  • Tumors in high-risk individuals were significantly smaller (median diameter of 2.5 cm vs. 3.6 cm). 2. Survival Rates  • The 5-year survival rate was significantly higher in high-risk individuals (50% vs. 9% in controls).  • High-risk individuals had a median OS of 62 months, compared to 8 months for controls.  • Fewer PDAC-specific deaths occurred in high-risk individuals (16% vs. 59% in 1-yr mortality; 43% vs. 86% in 5-yr). 3. Surveillance Methods  • Surveillance included annual endoscopic ultrasonography (EUS) or magnetic resonance imaging (MRI).  • Standard-of-care surgical and/or oncologic treatments were performed when necessary. 4. Study Population  • The study included 26 high-risk individuals and 1504 matched control patients.  • High-risk individuals were part of the Cancer of the Pancreas Screening (CAPS) program. 5. Statistical Analysis  • The study used conditional logistic regression, Cox proportional hazards regression, and competing risk regression models.  • Sensitivity analyses and adjustments for lead-time bias were conducted.   Title: Pancreatic Cancer Surveillance and Survival of High-Risk Individuals Authors: Amanda L. Blackford, Marcia Irene Canto, Mohamad Dbouk, et al. Published Date: July 3, 2024 DOI: 10.1001/jamaoncol.2024.1930

Lymphoepithelioma-like urothelial carcinoma is a rare kind of tumor which has only a little information in the literature. The article presents different therapies for the treatment of this rare disease, creating the hypothesis of performing a conservative treatment with a curative purpose. We know about the limitations of the methodology of the study, but these data could support an important information to decide how to treat this kind of tumor and to create a new hypothesis to perform a new treatment strategy and guidelines. We consider that we need more studies to understand its nature and prognosis.

prostate massage cancer prevention: The Wonders of Cancer prevention agents: Watchmen of Cell Wellbeing:Explore the potential link between prostate massage and cancer prevention. Uncover the wonders of antioxidants as protectors of cell health in the context of prostate health. Learn more about how these practices may contribute to overall well-being and potential cancer risk reduction. read now for blog post 👇👇 https://lnkd.in/dTthdQ8P

September is #bloodcancerawarenessmonth. MPNs are progressive blood cancers where bone marrow typically overproduces one of the mature blood elements. Other shared features include tendencies toward blood clotting/bleeding, organ enlargement, bone marrow scarring (fibrosis) and a possibility of transformation. Although MPNs can strike anyone at any age, most patients are afflicted in the sixth decade of life or later. At the MPN Canadian Research Foundation, we’re committed to funding researchers in their quest to treat and ultimately cure MPNs. Learn more: https://lnkd.in/gdmQSuVX #thisisbloodcancer #mpncanada #mpnresearch #mpnsm #canadianmpn

Delighted to share this work with co-authors from @mdandersoncancercenter and MUSC Hollings Cancer Center We looked at data from the Health Resources and Services Administration (HRSAgov), HHS data for #FQHCs and Centers for Disease Control and Prevention's BRFSS data for state estimates. The cross-sectional study includes 16 696 692 US adults served by approximately 1400 #FQHCs across the US. We found low breast, cervical, and colorectal cancer screenings. The contribution of the underscreened population served by FQHCs to the national underscreened general population was 16.9% for breast cancer, 29.7% for cervical cancer, and 14.7% for colorectal cancer screening. We conclude by highlighting the importance of examining practice-based data from the Health Resources and Services Administration (HRSAgov), HHS UDS for #FQHCs to generate insights into primary care settings that serve as safety nets for a significant proportion of the US population experiencing inequities! We call for appropriate resource allocations to improve cancer screening services for medically underserved populations in FQHCs and the need for systematic implementation efforts and #impsci to help address the unmet cancer screening needs in the US population.

Pancreatic cancer is a major global health concern, affecting a significant number of people worldwide. In this video, I discuss: Pancreatic cancer and the factors that increase your risk, including: 👉 Age (commonly diagnosed in Pakistan in patients above 50 years of age) 👉Smoking habits 👉Alcohol consumption 👉Diabetes 👉Obesity The importance of recognizing early warning signs such as unexplained weight loss and loss of appetite Effective diagnostic tools like tumor marker tests (CA 19-9, CEA) and imaging techniques (Tri-Phase CT Scan) Treatment options and the role of a gastroenterologist in helping patients navigate pancreatic cancer Early detection is critical for successful treatment! Watch the full video to learn in detail. #PancreaticCancer #PublicHealth #EarlyDetection #IGA #Healthcare 

Overall survival results were published from KEYNOTE-564.  This was a phase III trial comparing 1 year of adjuvant pembrolizumab vs placebo in high risk clear cell renal cell carcinoma after surgical resection.  The trial demonstrated a HR of 0.62 (0.44-0.87; p=0.005).  Another positive from this data is that the survival curves continue to separate after completion of pembrolizumab, showing that adjuvant treatment does not only delay time to recurrence, and has a long-term benefit.   Overall survival at 48 months was 91.2% in the pembrolizumab group and 86.0% in the placebo group, so around 1 in 20 patients benefited from the addition of this therapy.  It is important not to extrapolate these results to a lower-risk population, as that may be one of the reasons why adjuvant nivoluamb failed in renal cell carcinoma (CheckMate 914).  Given the clear overall survival benefit, we should be giving 1 year of pembrolizumab in all high risk patients after resection. #keytruda #kidneycancer https://lnkd.in/e9yVhiV8